We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.20 | 3.03% | 40.76 | 40.59 | 40.80 | 40.80 | 40.12 | 40.15 | 2,775,124 | 22:20:00 |
From Jul 2022 to Jul 2024
By Josh Beckerman
Shares of Sonnet BioTherapeutics Holdings Inc. were up 8% to $1.40 after it announced a clinical collaboration agreement with Roche Holding AG.
In Sonnet's first combination clinical study, Sonnet's SON-1010 and Roche's atezolizumab will be evaluated in patients with platinum-resistant ovarian cancer.
Sonnet expects to begin the study in the second quarter.
In October, Sonnet announced a collaboration agreement with Janssen Biotech Inc., which is part of Johnson & Johnson. It said SON-1010, SON-1210 and SON-1410 would be evaluated in combination with certain Janssen proprietary cell therapy assets.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 09, 2023 13:25 ET (18:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
